| Dear Voornaam
This Peer Review week, we want to say a big thank you to our committee and panel members, patient and public representatives and other reviewers who help us fund the most impactful research and accelerate the progress against cancer.
In the meantime, we’re exploring the future of publishing from different perspectives across the industry. We had a chat with Natalie Le Bot, a Chief Editor at Nature Communications, on a shift in the method of publishing that could improve research integrity, reproducibility and quality.
Read along to find out what publishers think of the future of publishing and how are they adapting. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
BOOST YOUR CAREER THROUGH OUR WOMEN OF INFLUENCE INITIATIVE Are you a female Cancer Research UK-funded fellow, group leader or postdoctoral scientist looking to take the next step in your research career? You can receive support from the most experienced women in business through our Women of Influence mentorship initiative.
By being paired with a leading businesswoman, you’ll have the opportunity to receive advice and insights from outside of academia on managing common experiences in the workplace. You’ll also have access to talks, skills workshops and a community of mentors and researchers for further support and networking. |
|
|---|
|
|---|
|
|
 NEW REQUIREMENTS ON SEX IN EXPERIMENTAL DESIGN We’ve put in place new requirements on integrating male and female sexes in the design of experiments described in all funding applications that involve animals, human and animal tissues and cells.
These new requirements will help build evidence around the role biological sex plays in cancer.
We’re rolling out this change gradually and we have scope to grant exceptions in robustly justified cases. Get in touch for support, or to discuss your questions or concerns on how the changes might apply to your research.
|
|
|---|
|  LAST CHANCE TO REGISTER FOR THE MOLECULAR ANALYSIS FOR PRECISION ONCOLOGY CONGRESS 2023 There's less than one week until the leading precision oncology congress, MAP 2023, takes place in Paris.
Join this event uniting researchers, people working on new technologies, medical doctors and healthcare providers and explore the latest data in the field of molecular profiling and precision medicine.
A new 'RoadMAP to the clinic' day will be held on 6 October, delving into the next wave of pan-cancer clinical trials. |
|
|---|
|
|---|
|
|
THE POTENTIAL OF CAR T-CELL THERAPY Austin was diagnosed with acute lymphoblastic leukaemia when he was two years old. In the latest podcast episode of That Cancer Conversation, Austin’s parents share how cancer has affected their family and how taking part in the T cell trial, CARPALL, has allowed Austin to be cancer free.
“There’s the leap of faith, there’s trusting us to try and do our best and trusting that this process might lead to better options for children in the future” says Sara Ghorashian, consultant haematologist and honorary senior clinical lecturer at UCL Great Ormond Street Institute of Child Health. Sara was lead scientist on the CARPALL trial and made Austin's CAR T-cells in the lab.
Hear more about Austin’s journey, Sara’s work on the trial and the Pac Man-like game she’s developing that helps children better understand their treatment. |
|
|---|
|
|---|
|
|
 ACCESS SEED-FUNDING TO TRANSLATE YOUR RESEARCH Are you interested in receiving funding to help turn your innovative ideas into cancer treatments, diagnostics or medical devices? The Cancer Research Horizons £15m+ Seed Fund can help you bridge the funding gap to achieve this.
Cancer Research Horizons, our innovation engine, has over 25 years’ experience establishing and growing over 60 startup companies, which have gone on to raise £2.3bn+ in investment.
If you would like to join this cohort, get in touch with the Cancer Research Horizons team. |
|
|---|
|  EXPLORE GRAIL AT OUR EARLY DETECTION OF CANCER CONFERENCE If you’re already registered to join us at the Early Detection conference in October, and have an interest in new technologies for detection, stop by GRAIL's stand for a chat.
GRAIL, our platinum sponsor, is a healthcare company using next-generation sequencing, population-scale clinical studies and state-of-the-art machine learning, software and automation to detect and identify cancer in earlier stages.
If you haven’t had a chance to register, we're unfortunately sold-out – but we're operating a waiting list.
|
|
|---|
|
|---|
|
|
 JOIN A LEADERSHIP PROGRAMME FOR BLACK, ASIAN AND ETHNICALLY DIVERSE RESEARCHERS StellarHE is recruiting its 2024 cohort of people aspiring to become leaders in higher education – and we’re sponsoring Cancer Research UK-funded researchers with a Black, Asian or ethnic background to take part.
The programme will equip you with skills and strategies to respond to the unique challenges and opportunities you may face through facilitated dialogue, experiential activities, reflective practice and coaching.
Express your interest by 30 October for the opportunity to take part. |
|
|---|
|  SUBMIT A NOMINATION FOR THE BIOCHEMICAL SOCIETY 2025 AWARDS The Biochemical Society 2025 Awards celebrates the achievements and diversity of the molecular bioscience community, and it's now open for nominations.
Recognise an individual, team or organisation for their work and give them a chance to receive a monetary prize and access career enhancing opportunities.
Categories include both specific and general fields of science. |
|
|---|
|
|---|
|
|
| | | Paris, France 04 October 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
| | | Liverpool, UK 18 October 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 20 October 2023 |
|
|---|
|
|---|
| | | Cambridge, UK 03 November 2023 |
|
|---|
|
|---|
| | | Edinburgh, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
